Peter Howarth
Overview
Explore the profile of Peter Howarth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Winders T, Fletcher M, Oppenheimer J, Howarth P, Antoun Z, van der Molen T, et al.
J Asthma
. 2025 Feb;
:1-11.
PMID: 39950743
Objective: Oral corticosteroids (OCS) are used to treat uncontrolled asthma, either as short rescue courses of treatment for severe disease exacerbations, or as long-term maintenance therapy in addition to other...
2.
DiBona D, Di Bona D, Paoletti G, Carlucci P, Spataro F, Weng S, et al.
J Asthma
. 2025 Jan;
1-11.
PMID: 39812421
Objective: Exacerbations and suboptimal disease control are common in severe asthma with an eosinophilic phenotype (SAep). Mepolizumab, an anti-interleukin-5 monoclonal antibody, has demonstrated efficacy and safety in randomized controlled trials...
3.
Lee J, Pollard S, Liu M, Schleich F, Pelaia G, Almonacid C, et al.
Ann Allergy Asthma Immunol
. 2025 Jan;
PMID: 39805551
Background: Some patients with severe asthma have overlapping allergic and eosinophilic phenotypes and may be eligible for anti-eosinophilic or anti-IgE biologics. Objective: This post hoc sub-analysis assessed real-world mepolizumab effectiveness...
4.
Bakakos P, Alobid I, Constantinidis J, Hellings P, Pfaar O, Taille C, et al.
J Allergy Clin Immunol Glob
. 2024 Nov;
4(1):100343.
PMID: 39554605
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma (SA) are 2 frequently coexisting conditions that are, in most cases, associated with eosinophilic inflammation. The concurrence of both diseases...
5.
Ishii T, Kunishige H, Kobayashi T, Hayashi E, Komatsubara M, Alfonso-Cristancho R, et al.
Mod Rheumatol
. 2024 Nov;
PMID: 39508562
Objectives: To provide long-term, real-world safety and effectiveness data for mepolizumab treatment in eosinophilic granulomatosis with polyangiitis in Japan. Methods: MARS (NCT04551989) was a real-world, observational study of patients who...
6.
7.
Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price R, et al.
Ann Med
. 2024 Oct;
56(1):2417184.
PMID: 39465531
Objectives: Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in...
8.
Benson V, Siddall J, Haq A, Small M, Tang Z, Ye T, et al.
J Asthma Allergy
. 2024 Oct;
17:1041-1054.
PMID: 39464421
Purpose: To inform effective management strategies for severe asthma in China, this study aimed to comprehensively characterize clinical characteristics, treatment patterns, disease control status, and healthcare resource utilization among patients...
9.
Kermani N, Chung K, Macis G, Santini G, Clemeno F, Versi A, et al.
Eur Respir J
. 2024 Oct;
64(5).
PMID: 39401856
Background: Lung quantitative computed tomography (qCT) severe asthma clusters have been reported, but their replication and underlying disease mechanisms are unknown. We identified and replicated qCT clusters of severe asthma...
10.
Benson V, Siddall J, Haq A, Small M, Alfonso-Cristancho R, Tang Z, et al.
J Asthma Allergy
. 2024 Oct;
17:949-964.
PMID: 39371223
Purpose: To inform better asthma management in China, this study aimed to comprehensively investigate clinical characteristics, treatment patterns, asthma control status, exacerbations, and humanistic burden among adult patients seeking hospital-based...